Extended Data Fig. 1: Practical quality control steps.
From: Pathology-oriented multiplexing enables integrative disease mapping
(a) Full elution of antibodies and (b) absence of remnant signals when re-staining with secondary antibodies. (c) Specificity of staining and constancy of re-stained structures over multiple imaging cycles. (d) Secondary-only cycles do not show signal amplification. (e) Re-staining of SOD1 after 61 cycles, showing very strong agreement between intensity distributions. vWF, von Willebrand factor; SRB1, Scavenger receptor class B member 1; PDI, Protein disulfide isomerase; EZR, Ezrin; p-rp-S6, phospho-ribosomal protein S6; p-H3, phospho-histone-H3; PCNA, Proliferating cell nuclear antigen; COL4, Collagen type IV; LAMP1, lysosomal-associated membrane protein 1;VMT, Vimentin; FN, Fibronectin; WT1, Wilms tumor 1; ACE2, Angiotensin-converting enzyme 2; CK19, Cytokeratin 19; ANXA3, Annexin 3; LTL, Lotus tetragonolobus lectin; α-SMA, alpha-smooth muscle actin (ACTA2); SYNPO, Synaptopodin; EMCN, Endomucin; NPHN, Nephrin; ab, antibody; AF, autofluorescence; PDPN, Podoplanin; LMN, Laminin; AQP2, Aquaporin 2; E-CAD, E-cadherin; SOD1: Superoxide Dismutase 1; HSD11B2: 11-β-hydroxysteroid dehydrogenase type 2; u-H2B: ubiquitylated histone 2B. Scale bars represent 100 µm.
